➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim
Mallinckrodt
Merck
McKesson

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Combretastatin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Combretastatin?

Combretastatin is an investigational drug.

There have been 19 clinical trials for Combretastatin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Thyroid Diseases. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.

There is one US patent protecting this investigational drug and twelve international patents.

Recent Clinical Trials for Combretastatin
TitleSponsorPhase
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerMateon TherapeuticsPhase 2/Phase 3
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDSMateon TherapeuticsPhase 1/Phase 2
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid CancerMateon TherapeuticsPhase 3

See all Combretastatin clinical trials

Clinical Trial Summary for Combretastatin

Top disease conditions for Combretastatin
Top clinical trial sponsors for Combretastatin

See all Combretastatin clinical trials

US Patents for Combretastatin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Combretastatin   Start Trial Anti-FGFR3 antibodies and methods using same Genentech, Inc. (South San Francisco, CA)   Start Trial
Combretastatin   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Combretastatin   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Combretastatin   Start Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Combretastatin   Start Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Combretastatin   Start Trial Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Combretastatin   Start Trial Antibody formulations GENENTECH, INC. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Combretastatin

Drugname Country Document Number Estimated Expiration Related US Patent
Combretastatin Argentina AR075939 2029-03-25   Start Trial
Combretastatin Australia AU2010229994 2029-03-25   Start Trial
Combretastatin Brazil BRPI1006448 2029-03-25   Start Trial
Combretastatin Canada CA2754163 2029-03-25   Start Trial
Combretastatin China CN102378767 2029-03-25   Start Trial
Combretastatin China CN104788564 2029-03-25   Start Trial
Combretastatin Colombia CO6450665 2029-03-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim
Mallinckrodt
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.